Adcendo Appoints Michael Pehl as Chief Executive Officer

Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record

Adcendo, a biotech company developing innovative antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces today the appointment of Michael Pehl as Chief Executive Officer (CEO). Henrik Stage, co-founder of Adcendo, will move to the role of Chief Financial Officer.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH